Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intepirdine (SB-742457) vs Donepezil vs Placebo in Mild-to-Moderate Alzheimer's
NCT00708552Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of intepirdine in Alzheimer's disease (AD) (4 arms), sponsored by GSK. Primary endpoints: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 24 weeks and Clinician's Interview-Based Impression of Change - Plus at 24 weeks. Started Jul 2008; status: completed.
02
Drugs
intepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00708552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00708552.